OCGN — Ocugen, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1372299 ·
Last close
$1.23
Market Cap
$416.38M
52W High
$1.90
52W Low
$1.16
ADV30
8,191,237
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,533,000 | — | -17,839,000 | -19,177,000 | 56,905,000 | 31,855,000 | 51,100,000 |
| Dec 2025 | -193,000 | — | -16,995,000 | -17,706,000 | 43,516,000 | 18,571,000 | 55,682,000 |
| Sep 2025 | 1,752,000 | — | -17,625,000 | -20,051,000 | 57,596,000 | 32,565,000 | 54,063,000 |
| Jun 2025 | 1,373,000 | — | -13,795,000 | -14,739,000 | 53,594,000 | 27,013,000 | 50,542,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,401,000
Investing CF
$-215,000
Financing CF
$53,557,000
CapEx
$-175,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-427,244,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-66,763,000
Pretax Income TTM
$-71,673,000
Interest Exp TTM
$5,223,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,465,000
EBITDA
$-63,870,000
Free Cash Flow
$-33,665,624
Enterprise Value
$417,822,880
Total Cash
$31,855,000
Total Debt
$33,296,000
Shares Out
338,521,856
Trailing EPS
$-0.24
Book Value
$0.02
ROE
-660.0%
ROA
-68.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,413,000 | -62,916,000 | -67,846,000 | 43,516,000 | 55,682,000 | — | -56,964,000 |
| Dec 2024 | 4,055,000 | -54,757,000 | -54,054,000 | 82,442,000 | 52,810,000 | — | -42,142,000 |
| Dec 2023 | 6,036,000 | -65,531,000 | -63,078,000 | 64,547,000 | 23,983,000 | — | -62,054,000 |
| Dec 2022 | 2,488,000 | -89,071,000 | -86,804,000 | 108,632,000 | 34,651,000 | — | -60,079,000 |
TTM Snapshot
Revenues TTM
$1,136,000
NetIncome TTM
$-12,970,000
OpCashFlow TTM
$0
Assets (Latest)
$82,442,000
Forward EPS
$-0.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNA | Ginkgo Bioworks Holdings, Inc. | $431.69M | $8.09 | — |
| STRO | SUTRO BIOPHARMA, INC. | $400.51M | $24.17 | — |
| CABA | Cabaletta Bio, Inc. | $436.99M | $2.68 | — |
| AUTL | Autolus Therapeutics plc | $396.55M | $1.49 | — |
| EDIT | Editas Medicine, Inc. | $395.93M | $2.58 | — |
News headlines (Yahoo Finance, 1h cache)
Ocugen to Participate in Upcoming August Investor Conferences
2026-07-31 11:02 · Yahoo
Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates
2026-07-30 22:00 · Yahoo
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Relat
2026-07-29 11:01 · Yahoo
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
2026-07-28 20:01 · Yahoo
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
2026-07-13 11:02 · Yahoo
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
2026-07-11 00:02 · Yahoo
Ocugen to Participate in Upcoming July Industry Conferences
2026-07-01 11:00 · Yahoo
Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst View
2026-06-25 00:23 · Yahoo
How The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst Guidance
2026-06-06 01:05 · Yahoo
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
2026-06-04 15:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.